Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
37.28
+0.07 (0.19%)
Apr 25, 2025, 12:33 PM EDT - Market open
Exelixis Revenue
In the year 2024, Exelixis had annual revenue of $2.17B with 18.49% growth. Exelixis had revenue of $566.76M in the quarter ending December 31, 2024, with 18.16% growth.
Revenue (ttm)
$2.17B
Revenue Growth
+18.49%
P/S Ratio
4.98
Revenue / Employee
$1,890,759
Employees
1,147
Market Cap
10.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
EXEL News
- 4 weeks ago - Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
- 4 weeks ago - Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - Business Wire
- 5 weeks ago - Exelixis Growth Continues with Big Money Boosts - FXEmpire
- 2 months ago - Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March - Business Wire
- 2 months ago - Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? - Benzinga
- 2 months ago - Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - Business Wire
- 2 months ago - Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 - Business Wire
- 2 months ago - Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit - Business Wire